HOME ABOUT US KEY PEOPLE NEWS & EVENTS LICENSED PRODUCTS TRANSPARENCY CAREERS CONTACT HOME STABILISATION SERVICES Highly labile products, such as live viral vector vaccines are not particularly suited to a conventional drying process. HydRIS platform has been proven to be highly successful in stabilising a range of live biologics: Live viral vector vaccines (adeno, MVA) Flavivirus listeria monocytogene based vector Range of live veterinary vaccines Range of extremely labile, protein based therapeutics ROOM TEMPERATURE STABLE VACCINES: The long term stability data has shown over 12 months stability at 37°C for the above live vaccines (including adeno and MVA vectors). cGMP MANUFACTURING CAPABILITY: Nova currently have in-house cGMP manufacturing capability to produce 5,000-10,000 units/batch Our live biologics manufacturing facility is authorised to handle organisms with BSL-1 and BSL-2 categories. The manufacturing process is scalable with the demand. CLICK on the HydRIS video to see how the technology works. Nova’s stabilisation platforms are based on a sugar-glass stabilization concept. The inspiration for this tech-nology arose from observations of anhydrobiotic organisms, such as the Resurrection Plant (Selaginella lepi-dophylla), which can protect themselves from extreme desiccation. Such organisms survive in drought condi-tions by producing high concentrations of particular sugars in their tissues. These sugars solidify as a glass during dehydration, preserving the cells and tissues in a state of suspended animation. When water is once again available the glass dissolves away, allowing normal biological functions to resume. In the course of adapting this natural process to stabilize pharmaceutical products, we have identified and de-veloped new and improved glass-forming materials and combined them, resulting in mixed glasses with ideal properties for stabilizing pharmaceuticals. Nova’s technology is based around two main platforms, known as VitRIS™ and HydRIS®, which are supplemented by ancillary technologies. This provides our scientists with the ability to tailor solutions that closely match the needs of our clients. VitRIS™ and HydRIS® deliver a number of benefits over traditional formulation methods (including those based on freeze-drying) which can be summarised as follows: Long term stability over a wide temperature range (from below 0ºC to > 50ºC) Physico-chemical stability in ready-to-inject formats Applicability to multi-component or binary drugs (e.g. multi-valent vaccines) Applicability to products requiring high concentration of active in stable liquids Compatibility with vaccine adjuvants (e.g. alum) Temperature stable rapidly dissolving powders Applicability to live bacteria, viruses and phages, and other highly labile products Based on gassed isolator technology, Nova has now finalised the cGMP sterile manufacturing process for the HydRIS® device which allows demonstration of the effectiveness of the device within clinical trial programmes. Watch our HydRIS video below: We have demonstrated that VitRIS™ can be successfully applied to a large number of pharmaceutical preparations including vaccines, insulin, monoclonal antibodies, peptides, proteins, enzymes and nucleic acids. Watch our VitRIS video below: The VitRIS™ platform is based on the well established industrial process of spray drying. In VitRIS™, the pharmaceutical product is formulated with water-soluble glass formers and dried as a solid, non-crystalline glass using an aseptically operated spray-dryer. The outcome of this first stage of the process is spherical, highly polished microspheres, in which the product is immobilised and stabilised. The microspheres produced have been shown to be thermally and physically stable over many years and can be engineered to be either solid ‘Vitrispheres’ with a typical diameter of approximately 3µm, or hollow ‘Aerospheres’ with a larger diameter approaching 20µm. The powder containing the stablilized API, obtained via spray-drying, can then be aseptically filled into any desired product container, including vials, injectors, infusion bags or 2 compartment syringes. Alternatively, the stable powder can be converted into a ready-to-inject format by suspension in an inert anhydrous liquid. These liquids are typically medically-approved fluorocarbons, hydrofluroethers or low density metabolisable oils. This second step requires the ability to match the density of the powder with the density of the liquid in order to prevent the powder either floating or sinking. Thermo-stable products offer significant practical advantages. They need no refrigeration, as they can be stored at elevated temperatures for long periods without significant loss of potency. They are also undamaged by freezing. Thermo-stable liquid products also offer the added advantages of requiring no preparation or re-constitution before injection. Changing the physical form of the microspheres generated during aseptic spray drying can dramatically alter their rate of dissolution. For example, Aerospheres are immediately soluble which removes any requirement for the prolonged reconstitution step normally associated with lyophilized products. While spray-drying technologies have been applied in a number of industries for many years, their use in the pharmaceutical industry has been limited by the fact that there were no spray driers operating under truly aseptic conditions. For several years Nova Laboratories have been offering cGMP aseptic spray drying services for the production of sterile, human-use, injectable material, which does not require a terminal sterilization process. Our spray drying facility has undergone numerous full scale media / process validation cycles, and is available for contract manufacturing. Watch our Aerosphere Technology (Instantly dissolving thermo-stable spray dried powder) video. Nova also offers aseptic filling of spray dried powder into a range of final fill volumes and presentations. Nova undertakes Proof-of-Concept spray drying trials for clients wishing to evaluate cGMP sterile spray drying for their products. Nova’s Development Laboratory is equipped with a range of laboratory-scale spray driers and supporting analytical techniques, to allow full characterisation of spray dried powder. We welcome speculative enquiries and applications from anyone with experience in the pharmaceutical industry, the right attitude and relevant qualifications. Latest Jobs Download all our latest product lists, and news articles from Nova Laboratories. Downloads About Us Products & Services Key People News & Events Careers Contact Us Privacy & Cookies Policy Clinical Manufacturing Specials Commercial Aseptic Manufacturing Stabilisation Technologies Support Services Nova Laboratories Ltd Martin House Gloucester Crescent, Wigston Leicester LE18 4YL T +44 (0)116 223 0100 F +44 (0)116 223 0101 E info@novalabs.co.uk W www.novalabs.co.uk Sign up to our monthly Newsletter and receive the latest news from Nova. Sign Up We use cookies to give you the best experience on our website - if you are happy click acknowledge & accept. Alternatively, you can find more information in our privacy policy. Acknowledge & Accept Code Nova-web001(1) / Date of preparation March 2015 © Copyright Nova Laboratories 2021|All rights reserved|Registered in England No. 918800 Site by Verto